Brain somatostatin receptor 2 mediates the dipsogenic effect of central somatostatin and cortistatin in rats: role in drinking behavior

Hiroshi Karasawa,1 Seiichi Yakabi,1 Lixin Wang,1 Andreas Stengel,1 Jean Rivier,2 and Yvette Taché1

1Department of Medicine, CURE/Digestive Diseases Center, Digestive Diseases Division, University of California at Los Angeles, and Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California; and 2The Clayton Foundation Laboratories for Peptide Biology, Salk Institute, La Jolla, California

Submitted 12 June 2014; accepted in final form 15 July 2014

Karasawa H, Yakabi S, Wang L, Stengel A, Rivier J, Taché Y. Brain somatostatin receptor 2 mediates the dipsogenic effect of central somatostatin and cortistatin in rats: role in drinking behavior. Am J Physiol Regul Integr Comp Physiol 307: R793–R801, 2014. First published July 16, 2014; doi:10.1152/ajpregu.00248.2014.—Intracerebroventricular injection of stable somatostatin (SST) agonists stimulates food and water intake in rats. We investigated the receptor subtype(s) involved in the dipsogenic effect of intracerebroventricular injection of SST agonists, mechanisms of action, and role. In non-fasted and non-water-deprived male rats with chronic intracerebroventricular cannula, intake of water without food or food without water was monitored separately to avoid any interactions compared with intracerebroventricular vehicle. SST-14 and cortistatin (CST-14) (1 μg/rat icv) increased water intake by 3.1- and 2.7-fold, respectively, while both peptides did not alter food intake at 1 h postinjection in the light phase. By contrast, the stable somatostatin agonist ODT8-SST (1 μg/rat icv) increased both water and food intake by 4.9- and 3.7-fold, respectively. S-346-011, a selective receptor 2 (sst2) agonist (1 μg/rat icv) induced water ingestion, while sst1 or sst4 agonist, injected under the same conditions, did not. The sst2 agonist S-406-028 (1 μg/rat icv) prevented the 1-h water intake induced by intracerebroventricular ODT8-SST and CST-14. Losartan (100 μg/rat icv), an angiotensin receptor 1 (AT1) antagonist, completely blocked the water consumption induced by intracerebroventricular ODT8-SST, whereas intracerebroventricular injection of S-406-028 did not modify the intracerebroventricular ANG II-induced dipsogenic response. The sst3 antagonist does not modify the decrease in the 3-h water intake in the early dark phase. These data indicate that SST-14 and CST-14 interact with sst2 to exert a potent dipsogenic effect, which is mediated downstream by angiotensin-AT1 signaling. These data also indicate that sst2 activation by brain SST-14 and/or CST-14 may play an important role in the regulation of drinking behavior.

angiotensin receptor 1; brain; cortistatin; somatostatin agonists; water intake

SOMATOSTATIN (SST) IS A CYCLIC NEUROPEPTIDE that is expressed in the central nervous systems (21, 62). The two endogenous isoforms of somatostatin, SST-14 and SST-28, interact with five distinct G protein-coupled receptors (sst), named sst1 to sst5 (49, 53). In addition to the originally described physiological actions to inhibit growth hormone release, somatostatin exerts several extrapituitary actions (29, 62) in keeping with the wide distribution of SST-14 and its receptors outside of the median eminence (21, 62). Namely, SST-14 or the stable pan-somatostatin agonist, ODT8-SST (1, 18) early on were reported to act in the brain to influence behavior, including food intake (20), sympathetic outflow, and visceral functions, namely, heart rate, blood pressure, and gastric secretion, and motility (7, 59). With regard to food intake, we recently showed that acute intracerebroventricular injection of ODT8-SST induces a potent sst2-mediated orexigenic effect in rodents (55–57), which was associated with an increase in drinking behavior assessed by the number of drinking approaches during the second hour postinjection (55, 57). Previous reports in rats also showed that the stable somatostatin agonist octreotide injected intracerebroventricularly increased water consumption when assessed without food for the 10-min period postinjection (30). In the presence of food, the peptide induced first a robust drinking within 1 min followed by eating after 10 min (4). These data are indicative of a dipsogenic effect, independent of food intake, induced by the activation of brain sst, which so far has been little documented outside of these reports (4, 30).

In particular, it is still unknown whether the native peptide SST-14 and the structurally related endogenous peptide cortistatin (14) act in the brain to stimulate drinking. Cortistatin is widely expressed in the brain with a selective distribution pattern, although regional overlaps exist with somatostatin (13). Cortistatin also activates sst1–sst5 with comparable binding affinities to those of SST-14 and SST-28 (53). However, cortistatin exerts distinct biological actions compared with somatostatin (6, 14), which have been ascribed to its specific binding affinity to ghrelin receptor (growth hormone secretagogue receptor 1a) (15), the orphan G protein–coupled receptor MrgX2 (51), or yet uncharacterized cortistatin receptor(s).

In the present study, we compared the orexigenic and dipsogenic effects of endogenous sst1–sst5 ligands, namely SST-14 and cortistatin, and of the long-acting pan-somatostatin agonist, ODT8-SST (18) injected intracerebroventricularly. As the feeding and drinking behaviors are closely related and usually occur concomitantly with 80% of spontaneous daily water intake being temporally associated with feeding in rats (3, 23), changes in ingestion of food or water can affect each other. In previous studies (4, 55–57) except one (30), food intake after intracerebroventricular injection of somatostatin agonists was assessed under normal conditions of feeding that include free access to food and water, and the observed food intake response could have been influenced by changes in water intake. Therefore, we first determined whether somatostatin agonists injected...
intracerebroventricularly induce orexigenic or dipsogenic effect in the light phase without access to water or food, respectively, to dissociate these two components. Then, we determined the sst subtype(s) involved in the dipsogenic effect using sst subtype-specific peptide analogs, namely the sst1 agonist S-406-062, sst2 agonist S-346-011, sst4 agonist S-315-297, and the sst2 antagonist S-406-028 recently developed (9, 17, 19).

Physiological relevance of brain sst2 signaling system during stimulate water intake in rats (22, 31). Lastly, we tested the responsive to intracerebroventricular ANG II or octreotide to tricular ODT8-SST activates brain sites previously shown to be (S-406-062, compound 25 in Ref. 19), selective sst2 agonist (S-ODT8-SST (compound 1 in Ref. 18), selective peptide sst1 agonist sst1–sst5 is yet not available.

**METHODS**

**Animals.** Adult male Sprague-Dawley rats were purchased from Harlan Laboratories (San Diego, CA) at an initial body weight of 230–250 g. Animals were kept under controlled illumination (12:12-h light-dark cycle, lights on/off: 6:00 AM/6:00 PM) and temperature (22 ± 2°C). Animals were fed standard rodent diet (Prolab RMH 2500; LabDiet, PMI Nutrition, Brentwood, MO), and tap water was available ad libitum. Animal care and experimental procedures followed institutional ethical guidelines and conformed to the requirements of the federal authority for animal research conduct. All procedures were approved by the Animal Research Committee at the Veterans Affairs Greater Los Angeles Healthcare System (animal protocol no. 11047-09).

**Peptides and compounds.** Structure, molecular weight, and binding affinity to human sst1–sst5 of SST-14, cortistatin-14 (CST-14), ODT8-SST (compound 1 in Ref. 18), selective peptide sst1 agonist (S-406-062, compound 25 in Ref. 19), selective sst2 agonist (S-346-011, compound 2 in Ref. 27), selective sst4 agonist (S-315-297, compound 14 in Ref. 17), and selective sst2 antagonist (S-406-028, compound 4 in Ref. 9) are detailed in Table 1. Peptides were designed, synthesized, purified, and characterized at

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Structure</th>
<th>MW</th>
<th>sst1</th>
<th>sst2</th>
<th>sst3</th>
<th>sst4</th>
<th>sst5</th>
</tr>
</thead>
<tbody>
<tr>
<td>SST-14&lt;sup&gt;41&lt;/sup&gt;</td>
<td>H-Ala-Gly-c[Cys-Lys-Asn-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys]-OH</td>
<td>1638</td>
<td>2.3</td>
<td>0.2</td>
<td>1.2</td>
<td>1.7</td>
<td>1.4</td>
</tr>
<tr>
<td>CST-14&lt;sup&gt;41&lt;/sup&gt;</td>
<td>H-Pro-c[Cys-Lys-Asn-Phe-Trp-Lys-Thr-Phe-Ser-Cys]-OH</td>
<td>1721</td>
<td>2.1</td>
<td>0.5</td>
<td>3.8</td>
<td>18</td>
<td>0.9</td>
</tr>
<tr>
<td>ODT8-SST&lt;sup&gt;18&lt;/sup&gt; sst1 agonist&lt;sup&gt;19&lt;/sup&gt;</td>
<td>H-c[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-OH</td>
<td>1079</td>
<td>27</td>
<td>41</td>
<td>13</td>
<td>1.8</td>
<td>46</td>
</tr>
<tr>
<td>S-406-062 sst2 agonist&lt;sup&gt;17&lt;/sup&gt;</td>
<td>H-D Tyr-c[Cys-DAgl(NMe2,naphthoyl)-IAmp-Phe-Cys]-Thr-NH&lt;sub&gt;2&lt;/sub&gt;</td>
<td>1238</td>
<td>0.2</td>
<td>&gt;1000</td>
<td>158</td>
<td>27</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>S-346-011 sst2 agonist&lt;sup&gt;17&lt;/sup&gt;</td>
<td>H&lt;sub&gt;2&lt;/sub&gt;N-CO-c[Cys-Phenylalanine]-DTrp-Lys-Thr-Cys]-Thr-NH&lt;sub&gt;2&lt;/sub&gt;</td>
<td>1133</td>
<td>&gt;1000</td>
<td>6.2</td>
<td>394</td>
<td>494</td>
<td>100</td>
</tr>
<tr>
<td>S-315-297 sst2 antagonist&lt;sup&gt;19&lt;/sup&gt;</td>
<td>H&lt;sub&gt;2&lt;/sub&gt;N-CO-c[Cys-Phe-Pheny- Trp-Lys-Thr-Cys]-OH</td>
<td>1137</td>
<td>650</td>
<td>&gt;1000</td>
<td>780</td>
<td>1.5</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>S-406-028</td>
<td>H&lt;sub&gt;2&lt;/sub&gt;N-pNO&lt;sub&gt;2&lt;/sub&gt;-Phe-c[DCys-Tyr-DAPht(Bcm)-Lys-Thr]-Cys]-2Nal-NH&lt;sub&gt;2&lt;/sub&gt;</td>
<td>1208</td>
<td>&gt;1000</td>
<td>2.6</td>
<td>384</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
</tbody>
</table>

Superscript numbers in the first column denote the references. *Derived from competitive ligand displacement assays in cells expressing the cloned human sst1–sst5 using <sup>125</sup>I-[Leu<sup>8</sup>]-Trp<sup>2</sup>-Tyr<sup>28</sup>]-SST-28<sup>17-19</sup> or <sup>125</sup>I-SST-14<sup>41</sup>. It is to note that binding affinity of the used sst agonists/antagonists on cloned rat sst1–sst5 is yet not available.

AJP-Regul Integr Comp Physiol • doi:10.1152/ajpregu.00248.2014 • www.ajpregu.org
Watson’s rat brain atlas (50). The immunoreactivity for c-Fos was visualized by the avidin-biotin-peroxidase complex (ABC) immunohistochemical technique, as previously described (62). Free-floating sections were incubated for two nights with rabbit polyclonal anti-Fos antibody (1:10,000; PC38, Millipore, Billerica, MA). Then, sections were incubated at room temperature for 1 h with biotinylated secondary goat anti-rabbit IgG (1:1,000; cat no. 111-067-003; Jackson Immunoresearch Laboratories, West Grove, PA) followed by 1-h incubation with the ABC (1:200; Vector Laboratories, Burlingame, CA). The chromagen was diaminobenzidine tetrachloride (0.025%) with hydrogen peroxide (0.01%). Then, sections were mounted, air-dried, dehydrated in ethanol, cleared in xylene, and coverslipped.

C-Fos-immunoreactive cells were observed by light microscopy (Axioskop II; Carl Zeiss, Jena, Germany). Coordinates of selected brain nuclei were identified with the Paxinos and Watson’s rat brain atlas (50) and are provided in millimeters from bregma: median preoptic nucleus (MnPO), +0.24 to −0.24; lateral hypothalamus (LH): −1.80 to −3.60; supraoptic nucleus (SON), −0.60 to −1.56; paraventricular nucleus (PVN), −1.44 to −1.80; and subfornical organ (SFO), −0.84 to −1.05.

Experimental protocols. Except otherwise stated, singly housed chronically intracerebroventricularly cannulated rats were placed in a cage with a grid floor 24 h before the experiment. Rats had free access to food and water, and the intracerebroventricular injection started between 3 and 4 h after the onset of lights on.

Experiment 1: effects of intracerebroventricular ODT8-SST, SST-14, and CST-14 on food intake assessed in rats without access to water. Vehicle (saline), ODT8-SST (1 μg/rat, 0.93 nmol), SST-14 (1 μg/rat, 0.61 nmol), or CST-14 (1 μg/rat, 0.58 nmol) was injected intracerebroventricularly, after which rats had free access to food without water. Food intake was monitored for 1 h after the intracerebroventricular injection. The dose of peptides was based on our previous studies showing a robust feeding response following intracerebroventricular SST-8 in rats with free access to food and water (55).

Experiment 2: effects of intracerebroventricular ODT8-SST, SST-14, CST-14, and subtype-selective sst agonists on water intake measured without food. Rats were intracerebroventricularly injected with vehicle (saline), ODT8-SST (1 μg/rat), SST-14 (1 μg/rat), or subtype-selective agonists to sst1, sst2, and sst3, as listed in Table 1 (all 1 μg/rat = 0.81, 0.88, and 0.88 nmol, respectively). Rats were placed back in their home cages with access to water without food. Water intake was measured at 10 and 60 min after the intracerebroventricular injection. The peptide doses were based on our previous studies on food intake with rats in 55, 57, 58.

Experiment 3: effects of intracerebroventricular sst2 antagonist on water intake induced by intracerebroventricular injection of ODT8-SST and CST-14. Rats received an intracerebroventricular injection of vehicle (saline) or the selective sst2 antagonist, S-406-028 (1 μg/rat, 0.83 nmol) immediately followed by an intracerebroventricular injection of either saline, ODT8-SST (1 μg/rat), or CST-14 (1 μg/rat). Rats were placed back in their home cages with access to water only. Water intake was measured at 10 and 60 min after intracerebroventricular injection. The intracerebroventricular sst2 antagonist dose was based on a previous study showing the blockade of intracerebroventricularly administered sst2 agonist-induced stimulation of food intake in rats with free access to food and water (55).

Experiment 4: effects of intracerebroventricular AT1 antagonist, losartan, and sst2 antagonist, S-406-028 on water intake induced by intracerebroventricular ODT8-SST and ANG II. Rats received an intracerebroventricular injection of saline, losartan (100 μg/rat), or S-406-028 (1 μg/rat) immediately followed by an intracerebroventricular injection of saline, ODT8-SST (1 μg/rat), or ANG II (52 ng/rat, 50 pmol). Rats were placed back in their home cages with free access to water only, and water intake was measured at 10 and 60 min after the intracerebroventricular injection. The losartan dose was based on a previous study (30) and that of ANG II was the minimal effective dose inducing a reproducible dipsogenic effect in our settings based on preliminary data.

Experiment 5: effects of intracerebroventricular ODT8-SST on c-Fos expression in brain areas involved in water intake. Rats were injected intracerebroventricularly with saline or ODT8-SST (1 μg/rat) and placed back in their home cages without food or water to avoid any confounding effect of differences in food and water intake between the two groups. At 90 min after the intracerebroventricular injection, rats were euthanized, and brains were processed for immunohistochemistry, and c-Fos immunoreactivity was assessed in the MnPO, LH, SON, PVN, and SFO.

Experiment 6: basal water intake before and after the lights off. Basal spontaneous water intake was measured for two consecutive 3-h periods starting 4 h before and immediately after the lights off in intracerebroventricularly cannulated untreated rats without access to food. During the 1-h period just before the lights off, rats had no access to food or water.

Experiment 7: effects of selective sst2 antagonist on water intake during the lights off period. One week after experiment 6 was performed, the same experiment was repeated except that during the 30-min interval before the lights off, rats were injected intracerebroventricularly with vehicle (saline) or S-406-028 (1 μg/rat) and returned to their home cages. Water bottles were placed back just before lights off at 6:00 PM, and water intake without food was measured at 1 and 3 h thereafter. Rats were refed at 3 h after the lights off, and food and water intake were measured 13 h later (4 h after the lights on). The experiment was performed in a cross-over design using six animals with a 4-day washout period between the measurements.

Statistical analysis. Data are shown as means ± SE. Comparison between two groups was performed by Student’s or Welch’s t-test following the F-test. Comparison among multiple groups was performed by 1-way or 2-way ANOVA followed by post hoc Tukey multiple comparisons. P < 0.05 was considered significant.

RESULTS

Experiment 1: intracerebroventricular ODT8-SST increased food intake assessed without water, while SST-14 and CST-14 did not. In rats with free access to food without water after the intracerebroventricular injection, ODT8-SST (1 μg/rat) significantly increased the 60-min cumulative food intake compared with intracerebroventricular vehicle (3.7 ± 0.8 vs. 1.0 ± 0.3 g; P < 0.05), while intracerebroventricular SST-14 or CST-14 (both 1 μg/rat) under the same conditions had no effect (Fig. 1).

Experiment 2: ODT8-SST, SST-14, CST-14, and sst2 agonist increased water intake measured without food. In rats with free access to water without food, the 10- and cumulative 60-min
water intake was significantly increased by the intracerebroventricular injection of ODT8-SST, SST-14, and CST-14 compared with vehicle (3.3 ± 1.2, 4.9 ± 0.6, and 4.0 ± 0.3 ml vs. 0.7 ± 0.3 ml at 10 min, respectively; 8.5 ± 1.2, 5.6 ± 0.5, and 4.8 ± 0.4 ml vs. 1.8 ± 0.4 ml at 60 min, respectively; P < 0.05; Fig. 2). However, only intracerebroventricular ODT8-SST maintained a significant increase in water intake during the 10–60-min period compared with intracerebroventricular vehicle (Fig. 2).

To elucidate the sst subtype responsible for the water intake occurring in the absence of food, we tested the subtype-selective peptide sst1, sst2, or sst4 agonists. The selective sst1, sst2, and sst4 agonists did not influence water intake monitored at 10 min postinjection (Fig. 3). However, during the 10–60-min period, the sst2 agonist, S-346-011 (1 μg/rat icv) significantly increased water intake (6.5 ± 1.2 vs. 1.1 ± 0.2 ml icv in vehicle; P < 0.01). The sst1 agonist and the sst4 agonist showed a trend to reduce the 10–60-min water intake, which did not reach statistical significance (Fig. 3). When the cumulative 60-min period of water intake was analyzed after the intracerebroventricular injection, there was a significant 4.7-fold increase induced by the sst2 agonist (8.5 ± 1.2 ml vs. 1.8 ± 0.4 ml in intracerebroventricular vehicle, P < 0.01) and no significant changes induced by intracerebroventricular sst1 and sst4 (Fig. 3).

In experiments 1 and 2, we also analyzed the food and water intake by normalizing values to individual body weight and found that it did not influence the significance of the results (body weight of rats before the start of experiments: 298 ± 20 g, means ± SD).

**Experiment 3:** the sst2 antagonist injected intracerebroventricularly blocked water intake induced by intracerebroventricular ODT8-SST and CST-14. To further establish the involvement of the sst2 receptor in the water intake response, we examined the influence of pretreatment with the sst2 antagonist, S-406-028 (1 μg/rat icv) on the drinking response to ODT8-SST and CST-14 (both 1 μg/rat icv). The antagonist by itself under these conditions did not influence the early light-phase water intake compared with intracerebroventricular saline (Fig. 4). However, the intracerebroventricular injection of S-406-028 just before that of ODT8-SST or CST-14 prevented the increased 10-min water intake (both P < 0.05; Fig. 4), and the cumulative water intake at 60 min in ODT8-SST-treated rats. Values did not differ significantly from those in rats treated with vehicle plus saline at either time. Two-way ANOVA showed a significant influence of antagonist treatment (F1,29 = 23.4; P < 0.001), agonist treatment (F2,29 = 18.5; P < 0.001), and antagonist × agonist treatment (F2,29 = 5.9; P < 0.01) on 10-min water intake; and a significant influence of antagonist treatment (F1,29 = 21.0; P < 0.001), agonist treatment (F2,29 = 27.8, P < 0.001), and antagonist × agonist treatment (F2,29 = 7.8; P < 0.01) on the cumulative 60-min water intake.

**Experiment 4:** the selective AT1 antagonist losartan injected intracerebroventricularly blocked intracerebroventricularly administered ODT8-SST-induced water intake, while the sst2 antagonist did not modify water intake induced by ANG II. The intracerebroventricular injection of losartan (100 μg/rat icv) given before that of ODT8-SST (1 μg/rat icv) completely blocked the water intake induced by ODT8-SST at 10 min (0.5 ± 0.1 vs. 4.3 ± 0.8 ml; P < 0.01) and at cumulative 60-min periods (1.2 ± 0.4 vs. 9.2 ± 0.5 ml; P < 0.01) after treatment (Fig. 5). In contrast, the selective sst2 antagonist S-406-028 (1 μg/rat icv) had no effect on the water intake induced by ANG II (52 ng/rat icv) either at 10 min or the cumulative 60 min (Fig. 5).
**DISCUSSION**

In the present study, we showed that the activation of brain somatostatin receptors by the native peptides SST-14 and CST-14 and the stable peptide agonist ODT8-SST injected intracerebroventricularly elicits a prompt stimulation of water consumption independently of food intake in rats. The dipsogenic action is primarily mediated by sst2 with the downstream involvement of ANG II-AT1 receptor signaling. We also demonstrated that the selective sst2 antagonist, S-406-028 injected intracerebroventricularly dampened the spontaneous 1-h water intake occurring in the early dark phase by 55%, while not
modifying ANG II’s dipsogenic effect in the light phase. These findings point to a physiological role of brain somatostatin-sst2 signaling in the stimulation of water ingestion.

SST-14 or CTS-14 injected acutely at −0.60 nmol into the lateral brain ventricle in chronically cannulated rats increased water intake by 3.1- and 2.7-fold compared with intracerebroventricularly vehicle-treated rats during the first 1 h postinjection in the morning of the light phase. This reflects independent mechanisms of those associated with food intake since rats had no access to food after intracerebroventricular injection. In addition, both SST-14 and CST-14 had no effect on food intake assessed without water under otherwise similar conditions. These data provide the first evidence that endogenous somatostatin ligands act in the brain to induce a potent dipsogenic effect in rats. The time course response indicates that both SST-14 and CTS-14 action was rapid in onset and short-lasting, as shown by the increase of water intake occurring during the first 10 min and the lack of significant changes in the subsequent 10–60 min period after intracerebroventricular injection. Likewise, the stable pan-somatostatin agonist ODT8-SST (18) induces a dipsogenic response of similar magnitude to that of SST-14 or CST-14 at 10 min; however, the effect was maintained during the 10–60 min period with a 4.7-fold increase compared with intracerebroventricular vehicle. The ODT8-SST long duration of action may be related to the stability of the peptide agonist compared with the short half-life of the native ligands (1), although differences in intracerebroventricular nanomolar doses between ODT8-SST (0.93 nmol) and SST-14 and CTS-14 (~0.60 nmol) may also play a role.

SST-14 and CST-14 and ODT8-SST display affinity to sst1-5 in the nanomolar range (Table 1) (53), and CST-14 can, in addition, bind to other receptors, including the ghrelin receptor (15, 51). However, the implication of the ghrelin receptor in CST-14 dipsogenic response can be ruled out since ghrelin intracerebroventricularly inhibits water intake in dehydrated rats monitored in the absence of food (32) and the dipsogenic response to intracerebroventricularly administered ANG II in rats (33, 44). The present study provides convergent pharmacological evidence of a primary role of brain sst2 in mediating the stimulation of water intake by intracerebroventricular CST-14 and the stable somatostatin agonist. First, the intracerebroventricular injection of the sst2 agonist, S-346-011 (27) (0.88 nmol) induces water intake, reaching a similar magnitude to that of intracerebroventricular ODT8-SST or CST-14 at 1 h postinjection. Second, the intracerebroventricular injection of the sst2 antagonist, S-406-028 (9) blocked the increase in water intake induced by both ODT8-SST and CST-14, as monitored at either 10 or 60 min after intracerebroventricular injection, while having no effect on basal light phase water intake. However, it has to be noted that the selective sst2 agonist enhanced drinking during the 10–60 min after injection but failed to do so during the first 10 min. Possible distinct physicochemical profiles between the sst2 agonist and native peptides or ODT8-SST that influence their brain diffusion may account for the differential time course in the onset of water intake. It is unlikely that it reflects the involvement of additional sst subtype(s) since the selective sst2 antagonist completely blocked the 10-min water intake stimulated by intracerebroventricular ODT8-SST and CST-14. Third, the selective sst1 (S-406-062) or sst5 (S-315-297) agonist (17, 19) injected under the same conditions showed a trend toward decrease in water intake. In line with these findings, previous reports showed that the stable sst agonist octreotide, which is devoid of sst5 and sst5 affinity, while binding to sst2 > sst5 >> sst5 (28), increased water consumption within the first 10 min after intracerebroventricular injection in picomolar range in rats that had no access to food (30).

The present study also showed that the nonpeptide AT1 receptor antagonist losartan (47) injected intracerebroventricularly blocked the drinking response induced by intracerebroventricular injection of ODT8-SST either at 10 or 60 min postinjection. Consistent with these findings, a previous report indicated that intracerebroventricular injection of saralasin, an antagonist of the AT1/AT2 receptors, and losartan prevented the initial 10-min drinking elicited by intracerebroventricular injection of octreotide in rats without food (30). There is also evidence that ANG II is released from the rat hypothalamus within 10 min of intracerebroventricular octreotide injection (25). By contrast the sst2 antagonist injected intracerebroventricularly at a dose blocking the dipsogenic effect of intracerebroventricularly administered ODT8-SST did not interfere with the drinking response to intracerebroventricularly administered ANG II. Collectively, these data support the involvement of brain ANG II-AT1 transmission downstream of the activation of sst2 in the dipsogenic action of intracerebroventricularly administered somatostatin.

The exact underlying neuroanatomical substrate(s) through which the activation of sst2 signaling by intracerebroventricular ODT8-SST recruits the brain ANG II-AT1 system (22, 43) will need to be further delineated. The SFO, organum vasculosum laminae terminalis (OVLT), and MnPO are among the major brain structures involved in the drinking response to ANG II acting on AT1 receptors (43). In particular, the dipsogenic effect of intracerebroventricular ANG II is abolished by the ablation of the anteroventral third ventricle (AV3V) (8), unlike SFO (42), suggesting the importance of AT1 receptors in the MnPO in the AV3V region. It may be speculated that intracerebroventricular ODT8-SST acts on sst2 receptors in the SFO and induce water ingestion by activating angiotensinergic pathways innervating the MnPO within the AV3V region. In support of this contention, microinjection of octreotide into the SFO induces water ingestion in rats (31). Somatostatin binding sites have been reported in the SFO (38, 39), although the receptor subtype(s) are still to be determined, and AT1 recep-

---

**R798**

**DIPSOCGENIC EFFECT OF SOMATOSTATIN ANALOGS**

---

**Fig. 7.** The selective sst2 antagonist blocked the physiological water intake in the early dark phase. Rats were injected (10 μl/rat icv) with vehicle (saline) or sst2 selective antagonist (1 μg/rat icv) 30 min before lights were turned off at 6:00 PM. Water intake without food was measured during the 0–1- and 1–3-h periods; then data were cumulated over the 0–3-h period. Data are expressed as means ± SE of 6 rats per group. *P < 0.05 vs. vehicle.
tors are expressed in the MnPO (43, 46). However, ODT8-SST, as well as the sst2 agonist injected intracerebroventricularly under similar conditions did not induce c-Fos expression in the SFO or MnPO, while a strong c-Fos expression is observed in the magnocellular neurons of the PVN and SON (Ref. 26, present study). These hypothalamic nuclei are part of angiotensin pathways descending from the SFO and OVLT (22, 45). Convergent studies have highlighted that ANG II injected intracerebroventricularly induced c-Fos expression selectively in four areas of the forebrain in rats: the SFO, MnPO, SON and PVN (34, 41, 46). Moreover, the AT1 receptor is coexpressed with c-Fos/c-Jun in those areas, prominently in the PVN and SON after intracerebroventricularly ANG II (46). Collectively, these data would be compatible with a network that involves intracerebroventricular ODT8-SST, stimulating the angiotensinergic drinking system by acting in the PVN and SON. This is also consistent with the report that octreotide microinjected into or around the PVN induces water ingestion (31). In addition, there is a robust expression of sst2 in the PVN, where the neuronal localization of this receptor subtype can mediate both postsynaptic and presynaptic actions (12, 16). ODT8-SST activating sst2 may target primary inhibitory neurons (40) that are directly or indirectly suppressing the angiotensinergic signals.

Although each of ODT8-SST-, SST-14-, or CST-14-induced dipsogenic effects, only ODT8-SST stimulated food intake when assessed separately without water. The orexigenic action of intracerebroventricular ODT8-SST or the sst2 agonist was well documented in rats with access to food and water (55–57). The present study clearly established that the orexigenic and dipsogenic effects of intracerebroventricular ODT8-SST can be regarded as parallel and independent mechanisms at least during the first hours postinjection, although they may act in concert thereafter. This is further supported by the similar 1-h food intake increment induced by intracerebroventricular ODT8-SST in the presence or absence of water tested under otherwise similar conditions (Ref. 57). The understanding of the differential selective dipsogenic effects of intracerebroventricular injection of SST-14 and CTS-14 vs. dipsogenic and orexigenic actions of intracerebroventricular injection of ODT8-SST may be related to differential pharmacokinetics of the peptides. The short half-life (2–3 min) of SST-14 and CST-14 vs. dipsogenic and orexigenic actions of intracerebroventricular injection of ODT8-SST may be related to differential pharmacokinetics of the peptides. The short half-life (2–3 min) of SST-14 and CST-14 (2) may not allow the peptide to reach brain sites regulating feeding behavior, while reaching those involved in thirst. We observed that rats injected intracerebroventricularly with ODT8-SST with access to both food and water, tend to drink water first, and, thereafter, start to eat (data not shown), similar to the pattern of the other stable sst agonist, octreotide, injected intracerebroventricularly in rats (4, 30).

One major finding of the present study is that the activation of brain sst2 contributes to the early nocturnal water intake. Physiologically, rats drink primarily in the dark phase (64), and this nocturnal rhythm in water intake is considered to be driven by the nocturnal rhythm in food intake (36, 37). However, as reported previously (23, 48) and observed in the present study, rats are keeping the nocturnal pattern of water ingestion, even without food, as shown by the 4.4-fold increase in the amount of water intake during the first 3 h after the lights off compared with the same period before the dark phase in rats without access to food. Convergent evidence supports the implication of brain somatostatin-sst2 signaling in the early dark-phase drinking. First, the native peptides SST-14 and CST-14 injected intracerebroventricularly at a low dose were devoid of an orexigenic effect, and the selective sst2 agonist elicited water intake of a similar magnitude during the light phase as the spontaneous water drinking occurring during the first hours of the dark phase. Furthermore, the selective sst2 antagonist injected intracerebroventricularly reduced the increase in spontaneous water intake occurring during the first 1 h by 55%, while not influencing 1-h water intake monitored at 4 h after the lights on. The partial suppression of the dark-phase water intake is unlikely to reflect submaximal dosing of the sst2 antagonist, since the peptide normalized a similar rise in water intake induced by intracerebroventricular ODT8-SST in the light phase. Lastly, convergent reports demonstrated that somatostatin content and release in the rat hypothalamus showed diurnal variations consistent with a surge of peptide release at the early onset of the dark phase compared with low levels of the peptide in the light phase (24, 35, 52). With regard to the involvement of cortistatin, the gene expression is mainly localized in the rat cerebral cortex and hippocampus, unlike the hypothalamus (54), and mRNA levels showed a circadian fluctuation with highest levels of prepro-cortistatin in the cortex recorded in the late dark phase (5). On the basis of the brain distribution and time course of diurnal variations of both peptides, it is suggested that hypothalamic somatostatin may be more prominently involved in the early nocturnal drinking response than cortistatin.

In conclusion, our study showed that the endogenous sst ligands, SST-14, CST-14, and the stable agonist ODT8-SST injected intracerebroventricularly elicited a prompt drinking response in rats without access to food. The dipsogenic effect of the peptides results mainly from the activation of brain sst2 signaling and requires downstream the integrity of the brain angiotensinergic AT1 transmission. There was no reciprocal interaction between these systems, as the ANG II drinking response was not altered by the sst2 antagonist injected intracerebroventricularly. Importantly, the 55% blockade of spontaneous water intake in the first 1 h after the lights off under conditions of selective blockade of the brain sst2 is indicative that the brain somatostatin-sst2 pathway plays an important role in the control of early nocturnal stimulation of water intake occurring without food intake.

Perspectives and Significance

The present findings open new venues in the understanding of mechanisms regulating drinking behavior pointing toward the importance of brain somatostatin-sst2 signaling upstream of the brain ANG II-AT1 transmission. However, the neuroanatomical circuitries that underlie the link between sst2-mediated dipsogenic action and the recruitment of brain ANG II-AT1 pathway are still to be elucidated. In particular, neuronal activation by intracerebroventricularly administered ODT8-SST or sst2 agonist in the magnocellular PVN and SON (26), unlike other neuroanatomical substrates (SFO, MnPO) responsive to ANG II (34, 41, 46), suggest an action via these hypothalamic sites. On the basis of the well-documented inhibitory action of somatostatin on neurotransmission (40), whether the sst2 pathway may inhibit inhibitory mechanisms.
regulating thirst (60), most likely GABAergic neurons around the PVN (10) will need to be assessed.

As SST-14 is one of the most robustly conserved peptides throughout the evolution of vertebrates (61), it may be hypothesized that its biological action to stimulate fluid intake may have a bearing with primitive adaptive dipogenic mechanisms to maintain body fluid homeostasis during vertebrate phylogeny.

ACKNOWLEDGMENT

The authors are grateful to Honghui Liang for her excellent technical support. J. Rivier is the Dr. Frederik Paulsen Chair in Neurosciences Professor.

GRANTS

This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grants P30-DK-41303 (Animal Core, to Y. Taché and L. Wang), and RO1-30110, and by the Veterans Administration Research Career Scientist Award (to Y. Taché).

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS


REFERENCES


31. Herbert J, Forsling ML, Howes SR, Stacey PM, Shiers HM. Regional expression of c-fos antigen in the basal forebrain following intraventric-


